US Food and Drug Administration officials have offered a clear warning against suggesting biosimilars are inferior or different from their reference products in promotional campaigns, indicating in new draft guidance that the statements likely would be misleading.
The draft guidance released on 3 February offers considerations for reference biologic and biosimilar sponsors when designing promotional labeling...






